“We have investigated the endocannabinoid system in the motor cortex of motor neuron disease (MND) patients.
We have confirmed that CB2 receptors are elevated in the motor cortex of MND patients associated with the reactive gliosis. This phenomenon is previous to neuronal losses. We also found CB2 receptors in cortical and spinal motor neurons.
These observations support that targeting this receptor may serve for developing neuroprotective therapies in MNDs.”